Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Patient Education Important to Promote Use of Generics
May 4, 2009
- BUSINESS NEWS IN BRIEF
May 4, 2009
- SSP Aims at ¥2 Bil. with Switch OTC Version of Diclofenac
May 4, 2009
- PhRMA to Support NHI Price Maintenance System: Mr Sekiguchi
May 4, 2009
- Magnesium Oxide Should Remain Class 3 OTC Drug: Society
May 4, 2009
- Korosho to Speed Up Development of Anticancer, Pediatric Drugs Using Supplementary Budget
May 4, 2009
- Focusing on the Task at Hand
May 4, 2009
- More Companies Show Interest in Collaborative Multinational Trials: Mr Nakagaki
May 4, 2009
- Taisho: Switch OTC Drug Containing Tiquizium Bromide
May 4, 2009
- R&D NEWS IN BRIEF
April 27, 2009
- CoreMed Expands Drug Development Support Services in Europe
April 27, 2009
- Potential Biomarker for Oxaliplatin Discovered: Prof. Tanigawara
April 27, 2009
- REGULATORY NEWS IN BRIEF
April 27, 2009
- Majority of Major Drug Firms Increase Hiring of New Graduates in 2009
April 27, 2009
- Coefficients for Generics for DPC Hospitals May Be Introduced
April 27, 2009
- Yokohama Clinic Starts Cancer Therapy Using Dendritic Cells
April 27, 2009
- PMDA Creates New Office to Review Anticancer Drugs
April 27, 2009
- Asahi Kasei Licenses Flivas to Dong-A
April 27, 2009
- BUSINESS NEWS IN BRIEF
April 27, 2009
- Otsuka Aims at Further Growth Driven by Its Own Products in Oncology, CNS
April 27, 2009
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…